Alogliptin-A Narrative Review Abinaya S.K1, Aanandhi M Vijey2,* 1Department of Pharmacy Practice, School of Pharmaceutical Science, Vels University (VISTAS), Chennai 2Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Science, Vels University (VISTAS), Chennai *Corresponding Author E-mail: hodpchemistry@velsuniv.ac.in
Online published on 17 October, 2017. Abstract Diabetes mellitus is a metabolic disorder that is characterised by raised blood glucose level in the body as a result of insulin resistance and pancreatic beta-cell failure and defects in insulin secretion or insulin action. Pharmacological therapy for the management of type II diabetes currently includes six classes of Oral Antidiabetic drugs. They are Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones, Dipeptidyl peptidase IV inhibitors (DPP4) and α-Glucosidase inhibitors. The five accessible DPP-4 inhibitors are sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, which are also called as “Gliptins”. Alogliptin has been well established as the treatment option in the management of type 2 diabetes. Alogliptin is available as three new combination which is used with diet and exercise which helps in further improvement of glycemic control. Alogliptin is a Pro-drug, in which the active substance is alogliptin benzoate. The main advantage of using alogliptin over other drugs in its class is that the selectivity for DPP-IV is much higher than the next closest competitor drug. The cost of drug acquisition is low and affordable both as a single drug or in combination when compared to other DPP4 inhibitors. Top Keywords DPP4-Dipeptide Peptidase inhibitor, GLP-1-glucagon-like peptide-1, GIP-glucose-dependent insulinotropic peptide, DM-Diabetes Mellitus. Top |